JP2022553888A5 - - Google Patents

Info

Publication number
JP2022553888A5
JP2022553888A5 JP2022552123A JP2022552123A JP2022553888A5 JP 2022553888 A5 JP2022553888 A5 JP 2022553888A5 JP 2022552123 A JP2022552123 A JP 2022552123A JP 2022552123 A JP2022552123 A JP 2022552123A JP 2022553888 A5 JP2022553888 A5 JP 2022553888A5
Authority
JP
Japan
Prior art keywords
subject
trophinetide
composition according
administered
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553888A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057627 external-priority patent/WO2021086892A1/en
Publication of JP2022553888A publication Critical patent/JP2022553888A/ja
Publication of JP2022553888A5 publication Critical patent/JP2022553888A5/ja
Priority to JP2025116586A priority Critical patent/JP2025148461A/ja
Pending legal-status Critical Current

Links

JP2022552123A 2019-10-28 2020-10-28 レット症候群の治療のための方法及び組成物 Pending JP2022553888A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116586A JP2025148461A (ja) 2019-10-28 2025-07-10 レット症候群の治療のための方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962927008P 2019-10-28 2019-10-28
US62/927,008 2019-10-28
US202063031201P 2020-05-28 2020-05-28
US63/031,201 2020-05-28
PCT/US2020/057627 WO2021086892A1 (en) 2019-10-28 2020-10-28 Methods and compositions for treatment of rett syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116586A Division JP2025148461A (ja) 2019-10-28 2025-07-10 レット症候群の治療のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2022553888A JP2022553888A (ja) 2022-12-26
JP2022553888A5 true JP2022553888A5 (https=) 2023-10-18

Family

ID=75715568

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552123A Pending JP2022553888A (ja) 2019-10-28 2020-10-28 レット症候群の治療のための方法及び組成物
JP2025116586A Pending JP2025148461A (ja) 2019-10-28 2025-07-10 レット症候群の治療のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116586A Pending JP2025148461A (ja) 2019-10-28 2025-07-10 レット症候群の治療のための方法及び組成物

Country Status (14)

Country Link
US (1) US20220339138A1 (https=)
EP (1) EP4051308A4 (https=)
JP (2) JP2022553888A (https=)
KR (1) KR20220106982A (https=)
CN (1) CN115335071A (https=)
AU (1) AU2020376801A1 (https=)
BR (1) BR112022008095A2 (https=)
CA (1) CA3156680A1 (https=)
CL (1) CL2022001079A1 (https=)
CO (1) CO2022007501A2 (https=)
IL (1) IL292617B2 (https=)
MX (1) MX2022004785A (https=)
TW (1) TW202116300A (https=)
WO (1) WO2021086892A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310045A (en) 2021-07-12 2024-03-01 Acadia Pharm Inc Crystalline forms of tropintide
WO2023242844A1 (en) * 2022-06-15 2023-12-21 Ramot At Tel-Aviv University Ltd. Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
WO2025262646A1 (en) * 2024-06-22 2025-12-26 Biophore India Pharmaceuticals Pvt. Ltd Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
WO2014130691A2 (en) * 2013-02-20 2014-08-28 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
WO2015013397A2 (en) * 2013-07-25 2015-01-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
GB2554064B (en) * 2016-09-01 2019-11-20 Jit Singh Shailinder An enteral feeding tube

Similar Documents

Publication Publication Date Title
Rasmussen et al. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis
JP2023519965A5 (https=)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JPH06102622B2 (ja) 肥満の治療
JP2022553888A5 (https=)
US20220151960A1 (en) Treatment of symptoms associated with female gastroparesis
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2022521233A5 (https=)
Gupta et al. Intermittent short duration therapy with fluconazole is effective for tinea capitis
US20130217775A1 (en) Treatment of symptoms associated with female gastroparesis
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
WO2004006908A1 (ja) 色素沈着改善治療薬
JP2023544249A5 (https=)
CN1332663C (zh) 用硝酸咪康唑治疗外阴阴道念珠菌病的药盒
JP2023516753A5 (https=)
EP2830605B1 (en) A combination medicament comprising phenylephrine and paracetamol
JP2024531799A5 (https=)
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
JP2024525760A5 (https=)
CN115350194A (zh) 一种药物组合及其应用
Miach et al. Double‐blind cross‐over evaluation of mazindol in the treatment of obese hypertensive patients
CN117858705A (zh) 使用抗病毒化合物和硝唑尼特进行治疗
JP2006508993A5 (https=)
CN105796543B (zh) U0126在制备治疗帕金森药物上的应用
JP2024518455A5 (https=)